TY - JOUR T1 - Covid-19 and Excess Mortality in Medicare Beneficiaries JF - medRxiv DO - 10.1101/2021.04.07.21254793 SP - 2021.04.07.21254793 AU - Scott Greenwald AU - Nassib G Chamoun AU - Paul J Manberg AU - Josh Gray AU - David Clain AU - Kamal Maheshwari AU - Daniel I. Sessler Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/10/2021.04.07.21254793.abstract N2 - We estimated excess mortality in Medicare recipients with probable and confirmed Covid-19 infections in the general community and amongst residents of long-term care (LTC) facilities. We considered 28,389,098 Medicare and dual-eligible recipients from one year before February 29, 2020 through September 30, 2020, with mortality followed through November 30th, 2020. Probable and confirmed Covid-19 diagnoses, presumably mostly symptomatic, were determined from ICD-10 codes. We developed a Risk Stratification Index (RSI) mortality model which was applied prospectively to establish baseline mortality risk. Excess deaths attributable to Covid-19 were estimated by comparing actual-to-expected deaths based on historical comparisons and in closely matched cohorts with and without Covid-19. 677,100 (2.4%) beneficiaries had confirmed Covid-19 and 2,917,604 (10.3%) had probable Covid-19. 472,329 confirmed cases were community living and 204,771 were in LTC. Mortality following a probable or confirmed diagnosis in the community increased from an expected incidence of about 4% to actual incidence of 7.5%. In long-term care facilities, the corresponding increase was from 20.3% to 24.6%. The absolute increase was therefore similar at 3-4% in the community and in LTC residents. The percentage increase was far greater in the community (89%) than among patients in chronic care facilities (21%) who had higher baseline risk. The LTC population without probable or confirmed Covid-19 diagnoses experienced 38,932 excess deaths (35%) compared to historical estimates. Limitations in access to Covid-19 testing and disease under-reporting in LTC patients probably were important factors, although social isolation and disruption in usual care presumably also contributed. Remarkably, there were 31,360 fewer deaths than expected in community dwellers without probable or confirmed Covid-19 diagnoses, representing a 6% reduction. Disruptions to the healthcare system and avoided medical care were thus apparently offset by other factors, representing overall benefit. The Covid-19 pandemic had marked effects on mortality, but the effects were highly context-dependent.Competing Interest StatementConflict of Interest Disclosures: Greenwald, Chamoun, Manberg, Clain and Gray are employees of and hold equity interest in Health Data Analytics Institute. Dr. Sessler is a paid consultant of and holds equity interest in Health Data Analytics Institute. Dr. Maheshwari received no compensation from Health Data Analytics Institute.Clinical TrialThis manuscript reports outcomes of a retrospective study on previously collected data by the Centers of Medicare and Medicaid.Funding StatementThe study was funded by Health Data Analytics Institute. The Robert Wood Johnson Foundation provides support for providing access to the Covid-19 RSI365 risk prediction models by academic researchers for non-commercial purposes via the HDAI API (https://www.hda-institute.com/api/). Conflict of Interest Disclosures: Greenwald, Chamoun, Manberg, Clain and Gray are employees of and hold equity interest in Health Data Analytics Institute. Dr. Sessler is a paid consultant of and holds equity interest in Health Data Analytics Institute. Dr. Maheshwari received no compensation from Health Data Analytics Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was determined to be exempt from informed consent requirements by the New England Institutional Review Board (https://www.wcgirb.com/). This research qualifies under the approved exempt category: "Research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if the investigator records the information in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects."All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual subject data used for our analysis are available to certain stakeholders as allowed by federal regulations and CMS policy. Requests for access to data to replicate these findings require an approved research protocol and DUA with CMS. For more information, contact the Research Data Assistance Center (ResDAC, http://www.resdac.org). http://www.resdac.org ER -